All In Biotech

BLA 761345 · Pfizer INC

Elrexfio

Elranatamab · Injection

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

CDER novel approval, Aug 14, 2023: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Aug 14, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

48

5 Phase 3, 30 recruiting

FAERS reports

1,158

989 serious, 279 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME • Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.2 , 2.5 ), Warnings and Precautions (5.1) ] . • Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions, can occur in patients receiving ELREXFIO. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment. Withhold ELREXFIO until the neurologic toxicity resolves or permanently discontinue based on severity [see Dosage and...

What it is approved for

From the label in effect Sep 14, 2026.

ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ELREXFIO is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T‑cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 )

Mechanism: Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 10, 2025 Supplement 3 · Efficacy OrphanLetterLabel
  • Aug 14, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterReviewLabel
1 products under this application
  • ELREXFIO · ELRANATAMAB 12MG · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Elranatamab" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cytokine release syndrome207
  • death115
  • malignant neoplasm progression87
  • pyrexia82
  • immune effector cell-associated neurotoxicity syndrome60
  • pneumonia59
  • fatigue58
  • cytomegalovirus infection reactivation57
  • off label use49
  • plasma cell myeloma45
  • rash45
  • infection44

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20235
2024190
2025556
2026407

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elrexfio (Elranatamab-Bcmm)

2024 spending

$413K

Beneficiaries

n/a

17 claims

Per beneficiary

n/a

$7,071.55 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$413,065

Part B: Elrexfio (Elranatamab-Bcmm) · HCPCS J1323

2024 spending

$33.1M

Beneficiaries

277

2,469 claims

Per beneficiary

$119,494

2024 ASP limit $180.15 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$33,099,870

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 18 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.